Rockville: Samsung Biologics, the biotech subsidiary of South Korea's Samsung Group, has announced the acquisition of a U.S.-based manufacturing facility from GSK plc, a British pharmaceutical company, for US$280 million. This acquisition represents Samsung Biologics' first production facility outside of South Korea.

According to Yonhap News Agency, the Rockville, Maryland facility boasts a production capacity of 60,000 liters of drug substances. This addition increases Samsung Biologics' total production capacity to 845,000 liters. The company's president and CEO, John Rim, stated that the acquisition enhances their ability to maintain a geographically diversified manufacturing network.

As a contract development and manufacturing organization (CDMO), Samsung Biologics is committed to supporting its partners in delivering therapies globally. The new site in Rockville is expected to be integral to these efforts. The company has expressed plans to further invest in expanding the facility's capacity and upgrading its technologies, underscoring a long-term commitment to bolstering the global supply chain and improving access to essential medicines.